DGX
Quest Diagnostics Inc
$208.05
-0.16 (-0.08%)
At close · Jul 9
Market Cap
$22.96B
Shares
110,696,429
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$11.04B
+11.8%
FY2025
Net Income
$992M
+13.9%
FY2025
Gross Margin
38.5%
+3.7pp
FY2020
Operating Margin
14.1%
+0.5pp
FY2025
Diluted EPS
$8.75
+13.8%
FY2025
Operating Cash Flow
$1.89B
+41.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $11.28B | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.4B | $7.21B | $7.49B | $7.44B | $7.15B | $7.38B | $7.39B | $7.26B | $7.46B | $7.25B | $6.7B | |
| $10M | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | — | — | — | — | — | — | — | |
| -$260M | -$264M | -$201M | -$152M | -$138M | -$151M | -$163M | -$175M | -$167M | -$151M | -$143M | -$153M | -$164M | -$159M | — | — | — | — | — | — | |
| $7.53B | $7.37B | $6.63B | $6.2B | $6.45B | $6.58B | $5.8B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | $4.33B | $4.37B | $4.36B | $4.28B | $4.32B | $4.26B | $3.97B | |
| — | — | — | — | — | — | $3.63B | $2.69B | $2.61B | $2.68B | $2.9B | $2.84B | $2.8B | $2.82B | $3.02B | $3.03B | $3.05B | $3.13B | — | — | |
| — | — | — | — | — | — | 38.5% | 34.8% | 34.59% | 36.25% | 40.19% | 37.85% | 37.63% | 39.46% | 40.88% | 40.98% | 42.03% | 42.03% | — | — | |
| $2B | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | $1.7B | $1.75B | $1.74B | $1.66B | $1.75B | $1.74B | $1.61B | |
| $152M | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | $79M | $75M | $61M | $33.11M | $37.06M | $37.29M | $27.9M | |
| $577M | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | $283M | $287M | $281M | $253.96M | $256.69M | $264.59M | $237.88M | |
| — | — | — | — | $55M | $13M | $14M | -$3M | $49M | $30M | $11M | $39M | $43M | $75M | — | — | — | — | — | — | |
| $9.67B | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.5B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | $5.67B | $6.18B | $6.41B | $5.98B | $6.1B | $6.03B | $5.61B | |
| $1.61B | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.1B | $1.17B | $1.28B | $1.4B | $983M | $1.48B | $1.2B | $987M | $1.28B | $1.36B | $1.22B | $1.09B | |
| — | 14.1% | 13.63% | 13.64% | 14.45% | 22.07% | 20.89% | 15.93% | 14.62% | 15.74% | 17.7% | 18.67% | 13.22% | 20.64% | 16.27% | 13.35% | 17.68% | 18.23% | 16.86% | 16.28% | |
| $2.19B | $2.13B | $1.84B | $1.7B | $1.87B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.7B | $1.3B | $1.76B | $1.49B | $1.27B | $1.54B | $1.62B | $1.49B | $1.33B | |
| $183M | — | — | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | — | — | $173.35M | $147.5M | $146.59M | -$185.48M | — | |
| $3.12M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $2.77M | $1.41M | $2.52M | $5.71M | — | |
| -$233M | -$238M | -$171M | -$132M | -$193M | $218M | -$87M | -$155M | -$175M | -$135M | -$191M | -$296M | -$160M | -$151M | -$133M | -$138M | -$108.6M | -$131.18M | -$171.72M | -$152.42M | |
| $28M | $42M | $19M | $26M | $44M | $78M | $75M | $57M | $44M | $35M | $39M | $23M | $26M | $24M | $26M | $29M | $29.56M | $33.21M | $29.74M | $26.97M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $3M | $3.3M | $6M | -$9.9M | — | |
| $1.38B | $1.32B | $1.18B | $1.13B | $1.24B | $2.6B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.1B | $823M | $1.32B | — | $856.23M | $1.18B | $1.23B | $1.05B | — | |
| $329M | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | $500M | $402M | $355M | $430.13M | $460.47M | $386.77M | $358.57M | |
| $1.02B | $992M | $871M | $854M | $946M | $2B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | $849M | $556M | $471M | $720.89M | $729.11M | $581.49M | $339.94M | |
| — | 8.99% | 8.82% | 9.23% | 9.57% | 18.49% | 15.16% | 11.11% | 9.77% | 10.43% | 8.94% | 9.46% | 7.48% | 11.88% | 7.53% | 6.37% | 9.93% | 9.78% | 8.02% | 5.07% | |
| $51M | $54M | $50M | $54M | $69M | $85M | $68M | $48M | $52M | $52M | $51M | $44M | $36M | $34M | $36M | $35M | $36.12M | $37.11M | $31.71M | $26.51M | |
| — | — | — | — | — | — | — | — | $733M | $769M | $642M | $706M | $549M | — | — | — | — | — | — | — | |
| $1.06B | $1.05B | $797M | $861M | $939M | $2B | $1.45B | $878M | $727M | $796M | $611M | $698M | $537M | $827M | $578M | $452M | $752.48M | — | — | — | |
| USD/shares | — | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | $5.58 | $3.49 | $2.95 | $4.08 | $3.91 | $2.99 | $1.76 |
| USD/shares | — | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | $5.54 | $3.46 | $2.92 | $4.05 | $3.87 | $2.96 | $1.74 |
| shares | — | 111M | 111M | 112M | 116M | 125M | 134M | 134M | 136M | 137M | 140M | 144M | 145M | 152M | 159M | 159M | 175.68M | 185.95M | 194.28M | — |
| shares | — | 113M | 113M | 113M | 118M | 128M | 136M | 136M | 139M | 140M | 142M | 145M | 145M | 153M | 160M | 160M | 177.32M | 187.8M | 195.96M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $10.72B in buybacks, $3.99B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Diagnostics & Research median 2.92×
EV/EBIT
—
Diagnostics & Research median 31.02×
P/E (TTM)
22.92×
Diagnostics & Research median 32.16×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Diagnostic Information Services Business | $10,785,000,000 | $9,614,000,000 | $8,976,000,000 | $9,609,000,000 | $10,494,000,000 | $9,139,000,000 | $7,405,000,000 | $7,204,000,000 |
| All Other Segments | $250,000,000 | $258,000,000 | $276,000,000 | $274,000,000 | $294,000,000 | $298,000,000 | $321,000,000 | $327,000,000 |
By Product & Service (USD)
| Component | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|
| Routine Clinical Testing Services | $4,293,000,000 | $3,836,000,000 | $4,206,000,000 | $4,217,000,000 | $4,006,000,000 |
| Genebased And Esoteric Testing Services | $2,878,000,000 | $2,098,000,000 | $2,620,000,000 | $2,409,000,000 | $2,449,000,000 |
| COVID19 Testing Services | $2,770,000,000 | $2,723,000,000 | $0 | $0 | — |
| Anatomic Pathology Testing Services | $553,000,000 | $482,000,000 | $579,000,000 | $578,000,000 | $612,000,000 |
| All Other Services | $294,000,000 | $298,000,000 | $321,000,000 | $327,000,000 | $335,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Diagnostic Information Services Business | $1,829,000,000 | $1,630,000,000 | $1,547,000,000 | $1,704,000,000 | $2,646,000,000 | $2,201,000,000 | $1,298,000,000 | $1,235,000,000 |
| All Other Segments | $32,000,000 | $33,000,000 | $34,000,000 | $20,000,000 | $29,000,000 | $39,000,000 | $42,000,000 | $47,000,000 |
| Corporate | -$305,000,000 | -$317,000,000 | -$319,000,000 | -$296,000,000 | -$294,000,000 | -$269,000,000 | -$109,000,000 | -$181,000,000 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Diagnostic Information Services Business | 17% | 17% | 17.2% | 17.7% | 25.2% | 24.1% | 17.5% | 17.1% |
| All Other Segments | 12.8% | 12.8% | 12.3% | 7.3% | 9.9% | 13.1% | 13.1% | 14.4% |
Key facts
CIK
1022079
CUSIP
74834L100
13F (30d)
69 filings
47 filers
Visit website
Investor relations